Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
Biohaven Pharmaceutical Holding (BHVN) Likely to Pre-Release NURTEC-OTD Sales - Cantor Fitzgerald
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $165 as Cantor Fitzgerald Sees 61% Upside
-
Pre-Open Stock Movers 07/07: (DARE) (OPNT) (BHVN) Higher; (BSQR) (IDYA) (LOAN) Lower (more...)
-
Companies with NDRs 4/28
-
Companies with NDRs 4/27
-
Companies with NDRs 4/26
-
Companies with NDRs 10/07
-
Companies with NDRs 6/25
-
Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)
-
Pre-Open Stock Movers 01/29: (LEE) (LB) (GE) Higher (BHVN) (EXTR) (XLNX) Lower (more...)
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $92 at Cantor Fitzgerald After European NDR
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $87 at Cantor Fitzgerald; 'More Scarcity Value, Cash, and Pipeline Visibility'
-
Biohaven (BHVN) Prices 6.977M Shares Common Offering at $43/Sh
-
Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares
-
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
-
Biohaven (BHVN) Prices 3.355M Share Offering at $37.25/Sh
-
Biohaven Announces Pricing of Public Offering of Common Shares
-
Cantor Raises Biohaven (BHVN) PT To $50 After CEO and CFO Meetings
-
Cantor Fitzgerald Starts Biohaven Pharmaceutical Holding (BHVN) at Overweight

